Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background—The formation of prostacyclin (PGI 2), thromboxane (TX) A 2, and isoprostanes is markedly enhanced in atherosclerosis. We examined the relative contribution of cyclooxygenase (COX)-1 and -2 to the generation of these eicosanoids in patients with atherosclerosis. Methods and Results—The study population consisted of 42 patients with atherosclerosis who were undergoing surgical revascularization. COX-2 mRNA was detected in areas of atherosclerosis but not in normal blood vessel walls, and there was evidence of COX-1 induction. The use of immunohistochemical studies localized the COX-2 to proliferating vascular smooth muscle cells and macrophages. Twenty-four patients who did not previously receive aspirin were randomized to receive either no treatment or nimesulide at 24 hours before surgery and then for 3 days. Eighteen patients who were receiving aspirin were continued on a protocol of either aspirin alone or a combination of aspirin and nimesulide. Urinary levels of 11-dehydro-TXB 2 and 2,3-dinor-6-keto-PGF 1α, metabolites of TXA 2 and PGI 2, respectively, were elevated in patients with atherosclerosis compared with normal subjects (3211±533 versus 679±63 pg/mg creatinine,P<0.001; 594±156 versus 130±22 pg/mg creatinine,P<0.05, respectively), as was the level of the isoprostane 8-iso-PGF 2α. Nimesulide reduced 2,3-dinor-6-keto-PGF 1α excretion by 46±5% (378.3±103 to 167±37 pg/mg creatinine,P<0.01) preoperatively and blunted the increase after surgery. Nimesulide had no significant effect on 11-dehydro-TXB 2 before (2678±694 to 2110±282 pg/mg creatinine) or after surgery. The levels of both products were lower in patients who were taking aspirin, and no further reduction was seen with the addition of nimesulide. None of the treatments influenced urinary 8-iso-PGF 2α excretion. Conclusions—Both COX-1 and -2 are expressed and contribute to the increase in PGI 2 in patients with atherosclerosis, whereas TXA 2 is generated by COX-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2994 · Cited by 3,045
Galis, Z. S., Sukhova, G. K., Lark, M. W., & Libby, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117619 · Cited by 2,539
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Low Density Lipoprotein Oxidation and Its Pathobiological Significance
Steinberg, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20963 · Cited by 1,642
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Meade, E. A., Smith, W. L., & DeWitt, D. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53294-4 · Cited by 1,256
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Self-citation
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., & Yusuf, S. (2002) · Circulation · doi:10.1161/01.cir.0000013777.21160.07 · Cited by 1,053
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Antioxidant Properties of Probiotic Bacteria
Wang, Y., Wu, Y., Wang, Y., Xu, H., Mei, X., Yu, D., Wang, Y., & Li, W. (2017) · Nutrients · doi:10.3390/nu9050521 · Cited by 917
Oxidative stress and metabolic syndrome
Roberts, C. K., & Sindhu, K. K. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.02.026 · Cited by 866
Coppinger, J. A., Cagney, G., Toomey, S., Kislinger, T., Belton, O., McRedmond, J. P., Cahill, D. J., Emili, A., Fitzgerald, D. J., & Maguire, P. B. (2004) · Blood · doi:10.1182/blood-2003-08-2804 · Cited by 814
Self-citationAldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Factors Associated with Oxidative Stress in Human Populations
Block, G. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf029 · Cited by 473
Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421446 · Cited by 373
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
Chenevard, R., Hürlimann, D., Béchir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000051361.69808.3a · Cited by 358
Cipollone, F., Prontera, C., Pini, B., Marini, M., Fazia, M., De Cesare, D., Iezzi, A., Ucchino, S., Boccoli, G., Saba, V., et al. (2001) · Circulation · doi:10.1161/hc3401.093152 · Cited by 351
Adverse Cardiovascular Effects of the Coxibs
Dogné, J.-M., Supuran, C. T., & Pratico, D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0402059 · Cited by 344
Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor
Takayama, K., Garcı́a-Cardeña, G., Sukhova, G. K., Comander, J., Gimbrone, M. A., & Libby, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204810200 · Cited by 337
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Rocha, R., Martin-Berger, C. L., Yang, P., Scherrer, R., Delyani, J., & McMahon, E. (2002) · Endocrinology · doi:10.1210/en.2002-220120 · Cited by 308
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 294
Caughey, G. E., Cleland, L. G., Penglis, P. S., Gamble, J. R., & James, M. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2831 · Cited by 283
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
Burleigh, M. E., Babaev, V. R., Oates, J. A., Harris, R. C., Gautam, S., Riendeau, D., Marnett, L. J., Morrow, J. D., Fazio, S., & Linton, M. F. (2002) · Circulation · doi:10.1161/01.cir.0000014927.74465.7f · Cited by 279
Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases
Oniszczuk, A., Oniszczuk, T., Gancarz, M., & Szymańska, J. (2021) · Molecules · doi:10.3390/molecules26041172 · Cited by 276
Bolli, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00414-5 · Cited by 258
Llorente-Cortés, V., Estruch, R., Mena, M. P., Ros, E., González, M. A. M., Fitó, M., Lamuela-Raventós, R. M., & Badimon, L. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.004 · Cited by 159
Metadata
- Authors
- Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J.
- Venue
- Circulation
- Published
- 2000-08-22
- Volume
- 102
- Issue
- 8
- Pages
- 840-845
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2053230224
- Cited by
- 377
- References
- 45
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.